Efficacy of Shalmali Ghrita and Nishakatakadi Ghanavati after Virechan Karma in the management of Madhumehaja Klaibya [Diabetes Mellitus induced Erectile Dysfunction (DMED)] – Standard controlled clinical trial - Nil

All India Institute of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1 Male patient in the age group of 25-50 years
•2 Patients giving a clinical history of erectile dysfunction and having IIEF - EF score of = 25
•3 Patients giving a clinical history of diabetes (DM Type II) and or Fasting blood sugar (FBS) more than 126 mg per dl up to 180 mg per dl and or Postprandial blood sugar (PPBS) more than 140 mg per dl up to 300 mg per dl
•4 Glycosylated hemoglobin (HbA1C) more than 6.5%, up to 12%.
•5 Early-diagnosed cases are to be included as per the following criteria:
•Patient accidentally diagnosed in routine check-up or when appeared with other complaints in the hospital.
•Patients already taking conventional medicines or Ayurvedic medicine and who fall within the inclusive criteria mentioned above will be taken into group A (control) and B (trial) respectively (dose adjustment can be done).
•Early diagnosed diabetic patients (Maximum 5 years of diabetic history).

•1.Patients having insulin-dependent DM (type 1) and receiving insulin
•2.Emergency conditions in cases of DM.
•3.Patients with acute or chronic liver disease with elevated liver enzymes.
•4.Patients were reported being hypersensitive to any of the proposed trial drugs.
•5.Participation in other clinical studies in the past 12 weeks.
•6.Takes psychotropic medications that raise blood glucose (e.g., atypical antipsychotics)
•7.Patients suffering from Uncontrolled Hypertension (more than 140 by 90mmHg), Hypothyroidism, Nephropathy, CAD (taking allopathy medication for same), and any other chronic comorbid condition.
•8.Patients suffering from STD, Carcinoma, AIDS, TB, congenital abnormalities of genital organs, other diseases like Phimosis, Ulceration, Hydrocele, Spinal cord lesions, etc.
•9.For any reason, the investigator may consider a subject inappropriate for participation in this study.

发起方